Clinical Study

Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?

Tracy L. Greer, Prabha Sunderajan, Bruce D. Grannemann, Benji T. Kurian, and Madhukar H. Trivedi

Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9119, USA

Correspondence should be addressed to Tracy L. Greer; tracy.greer@utsouthwestern.edu

Received 27 June 2013; Revised 14 October 2013; Accepted 15 October 2013; Published 19 January 2014

Academic Editor: Yvonne Forsell

Copyright © 2014 Tracy L. Greer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Cognitive deficits are commonly reported by patients with major depressive disorder (MDD). Duloxetine, a dual serotonin/noradrenaline reuptake inhibitor, may improve cognitive deficits in MDD. It is unclear if cognitive improvements occur independently of antidepressant effects with standard antidepressant medications.

Methods. Thirty participants with MDD who endorsed cognitive deficits at screening received 12-week duloxetine treatment. Twenty-one participants completed treatment and baseline and posttreatment cognitive testing. The Cambridge Neuropsychological Test Automated Battery was used to assess the following cognitive domains: attention, visual memory, executive function/set shifting and working memory, executive function/spatial planning, decision making and response control, and verbal learning and memory.

Results. Completers showed significant cognitive improvements across several domains on tasks assessing psychomotor function and mental processing speed, with additional improvements in visual and verbal learning and memory, and affective decision making and response control. Overall significance tests for executive function tasks were also significant, although individual tasks were not, perhaps due to the small sample size. Most notably, cognitive improvements were observed independently of symptom reduction on all domains except verbal learning and memory. Conclusions. Patients reporting baseline cognitive deficits achieved cognitive improvements with duloxetine treatment, most of which were independent of symptomatic improvement. This trial is registered with NCT00933439.

1. Introduction

Cognitive deficits are commonly reported by patients with major depressive disorder (MDD) [1, 2] and yet they remain poorly understood. The impairments most commonly associated with MDD are in the domains of executive function, selective attention, and verbal learning [1, 3]. On the other hand, generalized psychomotor slowing [4, 5] can also impact performance across several cognitive processes and domains. Impaired cognition is likely associated with difficulties in everyday tasks contributing to the high degree of psychosocial and functional impairments [6–8], reduced productivity [9], and disability associated with MDD [10, 11]. For example, difficulties with planning and organization can significantly impair daily activities such as one’s ability to take care of family-related matters (e.g., childcare or managing finances) or one’s ability to perform efficiently on the job [12]. In fact, a recent study examining performance-based assessment of functional skills (e.g., paying a bill or rescheduling an appointment) in Chinese participants with severe mental illness found that functional skills were significantly impaired in depressed individuals compared to healthy control participants [13]. Because cognitive impairments occurring with MDD have been associated with persistent functional impairment and disability, they warrant focused attention during the treatment of depression.

Cognitive benefits have been noted with the most commonly utilized antidepressants, although the results of these studies are inconsistent. Treatment with selective serotonin reuptake inhibitors (SSRIs) has resulted in improved attention, memory, and learning [14], and similar results have been obtained when comparing cognitive performance following...
oflife, andpooreroverall prognosis[6,25,26].

may contribute to increased risk of relapse, impaired quality
other residual symptoms of depression, such as insomnia,
withescitalopram[35],suggestingapotentialsuperiorbenefit
mental processing speed, and motor performance. Interes-
memory, working memory, set shifting, spatial planning,
or escitalopram and found that both improved declarative
nized that norepinephrine plays a similarly important role
in the prefrontal cortex[33] and that both neuromodulators have distinct roles to
increase extracellular 5-HT, norepinephrine, and dopamine
rat frontal cortex[31] and has been associated with
serotonergic and noradrenergic reuptake in humans[32].
Although much previous work on cognitive functioning
has stressed the importance of intact dopaminergic levels,
particular with respect to functions mediated by prefrontal
cortex, such as working memory, it is now being recog-
nized that norepinephrine plays a similarly important role
[33] and that both neuromodulators have distinct roles to
facilitate information processing in the prefrontal cortex
[33,34].

Recently, Herrera-Guzmán et al. [35,36] compared cog-
nitive function following treatment with either duloxetine
or escitalopram and found that both improved declarative
memory, working memory, set shifting, spatial planning,
mental processing speed, and motor performance. Interest-
ingly, duloxetine treatment resulted in greater improvements
in declarative and working memory than those achieved with escitalopram[35], suggesting a potential superior benefit
of SNRI compared to SSRI for cognitive impairments in
MDD. In addition, episodic memory and processing speed
improvements were reported to be at least partially inde-
dependent of improvements in depressive symptom severity
[35]. This is an important issue, because there is evidence
suggesting that cognitive impairments may be independent
of symptom severity[37], but there is also evidence suggest-
ging that changes in cognitive function are associated
with symptomatic improvement[15,38,39]. However, these

studies were not explicitly designed to test for this relation-
ship, and therefore are limited in their ability to explain
the relationship between symptom severity and cognitive
improvements. Furthermore, the Herrera-Guzmán [35,36]
studies excluded individuals with an incomplete response to
treatment (defined as less than 50% reduction of Hamilton
Rating Scale for Depression, 17-item [HRSD17] score at Week
4), suggesting that the potential effects of duloxetine on
cognitive function and the association with those changes to
symptom severity should be investigated across a full range
of treatment responses as opposed to a narrowly defined
subgroup.

The primary objectives of this study were (1) to assess the
effect of duloxetine treatment on cognitive function, using
the Cambridge Neuropsychological Test Automated Battery
(CANTAB; Cambridge Cognition 2004) [40] in young-
to-middle-aged adults with MDD, and (2) to examine the
relationship between changes in depressive symptom severity
and changes in cognitive function. A unique feature of this
study design was the entrance criterion requiring participants
to subjectively report significant cognitive impairment. In
addition, the use of a computerized testing battery allowed for
the examination of processing and response times, in addi-
tion to performance measures (e.g., percent correct, percent
errors, etc.). The cognitive domains selected for assessment
in this study are those that are most consistently reported as
impaired in depression (attention, visual memory, executive
function, decision making and response control, and verbal
learning and memory). Thus, we examined a wide range of
cognitive abilities that we hypothesized would improve with
duloxetine treatment. We also hypothesized that cognitive
improvements would be related to improvements in symp-
tom severity. Limited information exists regarding whether
effects on cognitive deficits can be seen independently of
the antidepressant effect. We believe direct investigation of
the effect of duloxetine on cognitive function in those who
directly report cognitive deficits is important to the field in
that it may help guide clinicians toward a treatment option
that will improve depression in general, while also specifically
targeting cognitive deficits associated with depression.

2. Methods

2.1. Participant Selection. Participants were recruited from
the community and from physician referrals. The protocol
and related documents (including informed consent) were
approved by the University of Texas Southwestern Medical
Center at Dallas Institutional Review Board. Prior to their
participation in the study, participants were given a full
explanation of the study procedures and possible side effects
of the study medication, and they had the opportunity
to have any questions answered about the study or study
participation. All participants provided written informed
consent.

Our target population was young- to middle-aged per-
sons with MDD who reported difficulties with concentration
and/or cognition as a part of their depressive syndrome, as
measured by a score of 2 or greater on the Inventory for
Depressive Symptomatology (IDS-C30) [41] item addressing this symptom (#15: Concentration and Decision Making, which is scored based on the following anchor points: 0—“no change in usual capacity to concentrate and decide”; 1—“occasionally feels indecisive or notes that attention often wanders”; 2—“most of the time struggles to focus attention or make decisions”; and 3—“cannot concentrate well enough to read or cannot make even minor decisions.”). Specific additional inclusion criteria were as follows: (1) ability and willingness to provide written informed consent; (2) primary diagnosis of nonpsychotic MDD; (3) age 18–45; (4) Screening and baseline Hamilton Rating Scale for Depression 17-item (HRSD17) [42] score greater than or equal to 16 or Clinical Global Impression Scale Severity (CGI-S) [43] score of at least 4; and (5) abstinence of alcohol and hypnotics for 12 hr prior to cognitive testing.

Exclusion criteria were as follows: (1) presence of significant comorbid medical condition based on laboratory test, physician information, or evidence at examination; (2) participant report or evidence (based on physical examination or laboratory tests) of existing liver disease; (3) presence of other psychiatric disorders that were not secondary to depression or that constituted high risk; (4) concomitant pharmacological or psychotherapeutic treatment (those expected to affect depressive symptoms or cognition); (5) failure to respond to 2 adequate courses of antidepressant in the current episode (as measured by the Antidepressant Treatment History Form [44]); (6) hospitalization for mental illness within the past year; and (7) currently pregnant, planning to become pregnant in the next year, or breastfeeding.

2.2. Screening. The Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician-Rated version (SCID-CV) [45], was administered to all potential participants to diagnose MDD and rule out excluded comorbid psychiatric disorders. The Antidepressant Treatment History Form [44] was used to assess previous treatment courses for the current episode. Participants received hematology, blood chemistry, thyroid function tests, liver function tests, urinalysis, and urine drug screen to rule out excluded medical conditions. A urine and/or serum pregnancy test was performed as clinically indicated, for all women of child-bearing potential. Participants met with a psychiatrist for a physical evaluation and confirmation of diagnoses.

2.3. Assessments

2.3.1. Cognitive Function. The National Adult Reading Test—Revised (NART-R) [46] was given at baseline to assess premorbid intelligence. Clinician-rated and self-reported cognitive function was assessed via the Inventory for Depressive Symptomatology item “Concentration and Decision Making.” CANTAB was used to assess pre- and post-treatment cognitive function and was administered by raters who were blinded to symptom severity assessments. CANTAB is a comprehensive neuropsychological testing battery that has been used to assess cognitive function in a wide variety of brain disorders, including mood disorders. Tasks were selected for use in this study based on their previous exhibition of differences in depressed patients as compared to healthy controls. The tasks selected represented each of the following domains, which were used to group task performance during analyses: Attention, Visual Memory, Executive Function/Set-Shifting and Working Memory, Executive Function/Spatial Planning, Decision Making and Response Control, and Verbal Learning and memory. In addition, these tasks measure specific domains (attention, perception, working memory, declarative memory, and effortful control) that are consistent with those included in the National Institute of Mental Health Research Domain Criteria (NIMH RDoC) initiative [47], which aims to reassess pathophysiology of chronic mental illnesses through a dimensional approach [48]. An overall description of each task assessed in this study is provided below.

(1) Attention Domain Tasks. Motor screening (MOT) screens for visual, movement and comprehension difficulties; big circle/little circle (BLC) is a simple attention measure that tests comprehension, learning, and reversal of a rule; reaction time (RTI) measures speed of response to both predictable and unpredictable visual stimuli.

(2) Visual Memory Domain Tasks. Delayed matching to sample (DMS) is an object recognition task using complex visual patterns in which the choice is presented either simultaneously with the sample or after a brief delay; paired associates learning (PAL) is a delayed response visual memory and learning task; pattern recognition memory (PRM) assesses visual spatial recognition memory.

(3) Executive Function/Set-Shifting and Working Memory Domain Tasks. Intradimensional/extradimensional shift (IED) examines set-shifting and flexibility of attention by testing both simple and more complex rule acquisition and reversal; spatial working memory (SWM) is an executive function task assessing retention and manipulation of items in working memory, with the ability for assessment of perseverative (redundant) errors.

(4) Executive Function/Spatial Planning Domain Task. Stockings of Cambridge (SOC) is an executive function task based on the Tower of London test that assesses spatial planning.

(5) Decision Making and Response Control Domain Task. Affective go/no-go (AGN) assesses information processing biases and inhibitory control for positive and negative stimuli.

(6) Verbal Learning and Memory Domain Task. Verbal recognition memory (VRM) is a measure of immediate and delayed verbal recall and recognition. Each task can generate multiple outcome measures (e.g., percent correct and response latency), as described in Table I.

2.3.2. Symptom Severity. The Hamilton Rating Scale for Depression, 17 item, (HRSD17) [42], and the 30-item Inventory for Depressive Symptomatology—Clinician-Rated (IDS-C30) [41] were administered by trained evaluators to assess
### Table 1: Description of cognitive function outcome measures.

| Task                          | Acronym | Outcome measure | Description                                                                 |
|-------------------------------|---------|-----------------|-----------------------------------------------------------------------------|
| **Attention**                 |         |                 |                                                                             |
| Big/little circle             | BLC     | Mean correct latency (ms) | Speed of response showing how quickly participant touched the correct stimulus after it was displayed on the screen |
|                               |         | Mean percent correct (%) | Percent of total correct responses                                           |
| Reaction time                 | RTI     | Five-choice movement time (ms) | Time taken to touch correct stimulus after release of the press pad |
|                               |         | Five-choice reaction time (ms) | Speed with which participant releases press pad in response to stimulus at one of five locations |
| **Visual Memory**             |         |                 |                                                                             |
| Delayed matching to sample    | DMS     | Percent correct (all delays) (%) | Percent of correct stimulus selection after stimulus was hidden at delays of 0 s, 4 s, and 12 s |
|                               |         | Percent correct (simultaneous) (%) | Percent of correct stimulus selection during simultaneous presentation of target stimulus and distractors |
|                               |         | Mean correct latency (all delays) | Average speed of response where correct stimulus was selected in trials in which stimulus was hidden at delays of 0 s, 4 s, and 12 s |
|                               |         | Mean correct latency (simultaneous) | Average speed of response where correct stimulus was selected in trials with simultaneous presentation of target stimulus and distractors |
| Paired associates learning    | PAL     | Mean trials to success | Total number of trials required to correctly locate patterns/number of successfully completed stages |
| Pattern recognition memory    | PRM     | Total errors (adjusted) | Total number of errors with adjustment for each stage not attempted due to previous failure |
|                               |         | Total trials (adjusted) | Total number of presentations required to correctly locate patterns in all stages |
|                               |         | Percent correct | Percent correct responses |
|                               |         | Mean correct latency (ms) | Mean time to respond correctly |
| **Executive Function/Set-Shifting and Working Memory** |         |                 |                                                                             |
| Intra/extradimensional set-shifting | IED   | Stages completed | Number of stages completed out of nine possible |
|                               |         | Pre-ED errors | Number of errors prior to the extradimensional shift |
|                               |         | EDS errors | Errors made in the extradimensional stage |
| Spatial working memory        | SWM     | Strategy | Number of times participant begins a search with the same box for 6- and 8-box problems |
|                               |         | Between errors (4, 6, and 8 boxes) | Times the participant revisits a box in which a token was previously found; errors calculated for 4-, 6-, and 8-box trials |
| **Executive Function/Spatial Planning** |         |                 |                                                                             |
| Stockings of Cambridge        | SOC     | Problems solved in minimum moves | Number of times participant successfully completed a test problem in the minimum possible number of moves |
|                               |         | Mean initial thinking time (2, 3, 4, and 5 moves) | Time taken to plan a problem solution for trials requiring 2, 3, 4, and 5 moves |
|                               |         | Mean subsequent thinking time (2, 3, 4, and 5 moves) | Speed of movement after the initial move has been made for trials requiring 2, 3, 4, and 5 moves |
| **Decision Making and Response Control** |         |                 |                                                                             |
| Affective go/no-go            | AGN     | Mean correct latency | Mean time taken to respond correctly to each target word stimulus in all assessed blocks. |
|                               |         | Total omissions | Total number of missed responses to targets in all assessed blocks |
|                               |         | Total commissions | Total number of responses to distractors in all assessed blocks |
severity of depressive symptoms. The 30-item Inventory for Depressive Symptomatology–Self-Report (IDS-SR) [41] was used to assess self-reported depressive symptoms. The IDS is a 30-item, depression-specific symptom severity rating scale, designed to measure the specific signs and symptoms of depression, including melancholic and atypical features. Symptom severity measures were collected at each study visit by evaluators who were blind to the results and status of the patient. Cognitivetestingoutcome measures (see Table 1) were examined for normality. Seven measures were removed from subsequent multivariate analyses because of lack of variation in the task performance (e.g., ceiling or floor effects): BLC mean percent correct, DMS percent correct (simultaneous), and IED stages completed and four VRM measures: immediate free recall total novel words, immediate free recall total perseverations, immediate recognition total false positives, and delayed recognition total false positives. Four additional measures were removed from subsequent analyses—the SOC measure subsequent thinking time for 2-, 3-, 4-, and 5-move problems—because many people took longer to physically move the balls than they did to think about the moves, resulting in the absence of a calculation for this measure. This was most common for 2-move problems and decreased with each increasing number of moves.

2.4. Medication Management. Participants began open-label 12-week treatment with duloxetine at a starting dose of 30 mg per day for the first four days of treatment and then increased to 60 mg per day. Dosage changes were allowed at Weeks 2, 3, 6, and 9 to a maximum of 120 mg per day depending on the side effect profile, tolerability, and symptomatology. Dosage remained constant during Weeks 9–12 of the study, unless side effects or safety warranted a change. Decisions regarding changes in dose were guided by the principles of measurement-based care (MBC) [49] and aided by administration of the 16-item Quick Inventory for Depressive Symptomatology–Clinician-Rated (QIDS-C16). Scores ≤5 resulted in continuation of the current dose, scores between 6 and 8 allowed the clinician to choose whether or not to increase or maintain the current dose, and scores ≥9 resulted in a dose increase. These MBC principles were used successfully in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study [49, 50].

Participants met the study psychiatrist at all study visits to assess suicidality, side effects, adverse events, alcohol consumption, and improvement. In addition to the QIDS, the psychiatrist administered the Clinical Global Impression Scale (CGI) [43] to assess the overall impression of the participants’ symptom severity and overall change from baseline. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) [51] and Patient Rated Inventory of Side Effects (PRISE) scales were used to assess the frequency, intensity, and degree of functional impairment associated with side effects of duloxetine and the specific types of adverse effects (e.g., sleep and sexual function). Liver function tests were repeated during the course of the study at the study visit following a dose increase to 90 or 120 mg, or if symptoms of liver toxicity were present or suspected at any time during the study.

2.5. Statistical Analyses. Prior to conducting analyses all cognitive testing outcome measures (see Table 1) were examined for normality. Seven measures were removed from subsequent multivariate analyses because of lack of variation in the task performance (e.g., ceiling or floor effects): BLC mean percent correct, DMS percent correct (simultaneous), and IED stages completed and four VRM measures: immediate free recall total novel words, immediate free recall total perseverations, immediate recognition total false positives, and delayed recognition total false positives. Four additional measures were removed from subsequent analyses—the SOC measure subsequent thinking time for 2-, 3-, 4-, and 5-move problems—because many people took longer to physically move the balls than they did to think about the moves, resulting in the absence of a calculation for this measure. This was most common for 2-move problems and decreased with each increasing number of moves.

The remaining measures from the CANTAB battery that met analysis criteria were grouped into sets based on the cognitive domains they represented and were analyzed via separate multivariate analyses (MANCOVA and/or MANOVA, as described below) to account for multiple comparisons. In addition, this also gives the advantage of allowing examination of a collection of highly related variables together, providing additional sensitivity to changes within
that domain, which can be followed by separate analyses to determine if the effect is general or associated with a particular test or tests. Therefore, if a significant overall effect was found, secondary analyses (i.e., t-tests) were conducted to determine significance for individual measures. In order to determine the extent to which changes in cognition are associated with changes in symptom severity, a hierarchical analysis approach was utilized [52]. The first step was to use a MANCOVA which included depression symptom severity (based on HRSD17 score) as a covariate. If no changes were found, the second step involved conducting the analyses with the covariate removed. Note that age, education, and estimated intelligence were not needed because participants served as their own control. Normed scores were provided when calculated by CANTAB.

3. Results

Sixty-four individuals signed informed consent and were screened for participation in the study. Thirty-four individuals were excluded during the screening process for the following reasons: presence of significant comorbid medical condition or abnormal laboratory values (n = 12), presence of other psychiatric disorder or severity of symptoms (n = 9), declining further participation (n = 2), failing to follow up (n = 8), outside age criterion (n = 1), and prohibited concomitant medication (n = 2).

Thirty participants were found to be eligible for the study, received a baseline evaluation, and began study medication. Nine participants withdrew prior to study completion. Six had intolerable side effects (two had excessive sedation, one had an allergic reaction, one had insomnia, one had fatigue and insomnia, and one had fatigue, insomnia, and decreased appetite). One serious adverse event occurred for a participant who had acute pancreatitis secondary to gallstone obstruction. This participant had elevated liver enzymes that resolved after medical management of the event. The participant was discontinued from study participation and referred to follow-up care for depression. Two participants withdrew consent and were lost to followup.

Twenty-one participants completed all 12 weeks of study participation. The mean medication dose at Week 12 was 90 mg/d (± 28.5). One participant continued throughout the study at 30 mg and was not raised to 60 mg at the discretion of the physician; however, data was included in the analysis based on the intent-to-treat principle. Baseline demographic and clinical characteristics of these individuals are presented in Table 2.

3.1. CANTAB. The MANCOVA for verbal learning and memory revealed a significant relationship between change in symptom severity and change in verbal learning and memory (time × severity, $F(1,19) = 12.1$, $P < .003$; time × severity × verbal learning and memory, $F(2,18) = 0.60$, $P < .56$). To understand the nature of this effect, we conducted additional MANOVAs to examine the relationship between change in HRSD17 and each of the verbal learning and memory tasks. The immediate free recall task was significantly associated with change in HRSD17 (time × severity, $F(1,19) = 11.5$, $P < .004$), with a correlation between percent change in HRSD17 and percent change in immediate free recall of $r = .54$ (see Figure 1). The two verbal recognition tasks (both immediate and delayed) were not significantly associated with change in symptom severity.

The results of the MANCOVAs using percent change in HRSD17 as the measure of symptom severity change produced no significant effects in the remaining cognitive domains: Attention (Time × Severity, $F(1,19) = .17$, $P < .69$), Time × Severity × Attention, $F(2,18) = .34$, $P < .72$), Visual Memory (Time × Severity, $F(1,19) = .22$, $P < .65$), Time × Severity × Visual Memory, $F(7,13) = .55$, $P < .79$), Executive Function/Spatial Planning (Time × Severity, $F(1,19) = 1.27$, $P < .28$; Time × Severity × Executive Function/Spatial Planning, $F(6,15) = .58$, $P < .72$), Decision Making and Response Control (Time × Severity, $F(1,19) = .13$, $P < .73$), Time × Severity × and Decision Making and Response Control, $F(6,15) = 1.43$, $P < .27$). Therefore the symptom severity covariate was dropped from the analysis and only the MANOVAs are reported below, indicating that the changes in cognitive function are independent of change in symptom severity.

Significant domain-by-time interactions were obtained for all of the cognitive domains assessed: Attention ($F(2,19) = 68.79$, $P < .0001$), Visual Memory ($F(7,14) = 76.64$, $P < .0001$), Executive Function/Set-Shifting and Working Memory ($F(5,16) = 80.58$, $P < .0001$), Executive Function/Spatial Planning ($F(4,17) = 15.95$, $P < .0001$), and Decision Making and Response Control ($F(2,19) = 802.04$, $P < .0001$). Post hoc analyses revealed significant improvements on specific
Table 2: Participant baseline characteristics.

| Baseline variable | Noncompleters (N = 9) | Completers (N = 21) (analyzable sample) |
|-------------------|-----------------------|----------------------------------------|
|                   | Mean or % SD          | Mean or % SD                            |
| Age (years)       | 32.1, 7.8             | 31.3, 6.6                               |
| Male (%)          | 44.4                  | 33.3                                    |
| Female (%)        | 55.6                  | 66.7                                    |
| White (%)         | 66.7                  | 57.1                                    |
| Black (%)         | 11.1                  | 19.1                                    |
| Hispanic (%)      | 22.2                  | 23.8                                    |
| Education (years)*| 13.7, 6.4             | 14.2, 3.5                               |
| Characteristics of depression | | |
| Age of onset (years) | 22.3, 8.0 | 18.8, 7.6 |
| Length of current episode (months) | 58.9 (Median = 12.0) | 36.5 (Median = 6.0) |
| Number of previous episodes | 2.7, 1.3 | 2.8*, 2.0 |
| Baseline symptom severity | | |
| HRSD17          | 18.8                  | 19.4                                    |
| IDS-C30         | 35.8                  | 36.8                                    |
| IDS-SR30        | 36.2                  | 37.9                                    |
| Estimated intelligence | | |
| NART-R          | 107.3                 | 106.6                                   |

* n = 17.  
* n = 18; 3 participants not included because they indicated the number of previous episodes were too many to count.

SD: standard deviation; HRSD17: Hamilton Rating Scale for Depression, 17 items; IDS-C30: Inventory for Depressive Symptomatology—Clinician-Rated, 30 items; IDS-SR30: Inventory for Depressive Symptomatology—Self-Report, 30 items; NART-R: National Adult Reading Test-Revised.

3.2. Subjective Cognitive Function. Clinician-rated evaluation of cognitive function (based on the Inventory for Depressive Symptomatology item 15—Concentration and Decision Making) also improved following 12 weeks of duloxetine treatment. The mean item 15 score decreased from 2.14 ± 0.36 at baseline to 0.62 ± 0.74 after treatment. Similarly, the IDS Self-Report item (#15) decreased from a mean of 2.05 ± 0.76 to 0.52 ± 0.68, also indicating subjective cognitive improvement.

3.3. Symptom Severity. Changes in HRSD17 over the 12 weeks of treatment showed that participants’ depressive symptom severity improved significantly, with a mean score of 19.4 (4.4) at baseline, dropping to a mean score of 8.3 (3.7) at Week 12, corresponding to an average decrease of 54.5% (P < 0.0001). The IDS-C30 and IDS-SR30 scores showed similar decreases from baseline mean scores of 36.8 (8.7) and 37.9 (12.1), respectively, to Week 12 scores of 14.7 (10.0) and 13.7 (11.4). Twelve of the 21 completers (57.1%) were defined as responders (i.e., a 50% or more decrease in the HRSD17), and those same individuals were remitters, defined by a score of 7 or less on the HRSD17.

3.4. Adverse Effects. Participants completed the PRISE at each study visit, which assess participants’ reports of adverse effects in a variety of categories, regardless of whether or not the effects are attributed to medication. Adverse effects most commonly reported by participants who completed the study (n = 21; reported as percent occurrence across all observed visits (n = 145)) included difficulty sleeping (55.9%), headache (44.1%), poor concentration (43.5%), fatigue (43.5%), anxiety (40.0%), dry mouth (33.8%), decreased energy (33.1%), and loss of sexual desire (30.3%). Side effects occurring between 20.0–29.9%
Table 3: Performance on cognitive outcome measures before and after duloxetine treatment.

| Task | Outcome measure | Pretreatment Mean (SD) | z-score mean | z-score (SD) | Posttreatment Mean (SD) | z-score mean | z-score (SD) | ES |
|------|-----------------|------------------------|--------------|--------------|------------------------|--------------|--------------|----|
| BLC  | Mean correct latency | 726.1 (135.2) | 0.07 | 1.12 | 684.7 (123.3) | 0.38 | 1.06 |     |
|      | Mean percent correct | 99.9 (0.6) | -0.19 | 1.51 | 100.0 (0.0) | 0.16 | 0 |     |
| RTI  | Five-choice movement time | 480.7 (108.3) | | | 432.4 (91.5) | | | 0.48 |
|      | Five-choice reaction time | 415.6 (121.4) | | | 378.1 (52.3) | | |     |
| DMS  | Percent correct (all delays) | 83.2 (9.8) | | | 94.3 (6.4) | | | -1.37 |
|      | Percent correct (simultaneous) | 98.1 (6.0) | | | 97.1 (7.2) | | |     |
|      | Mean correct latency (all delays) | 3656.2 (1058.4) | | | 2958.8 (727.0) | | | 0.78 |
|      | Mean correct latency (simultaneous) | 2926.9 (941.3) | | | 2672.4 (573.3) | | |     |
| PAL  | Mean trials to success | 1.6 (0.5) | | | 1.6 (0.7) | | |     |
|      | Total errors (adjusted) | 10.4 (10.0) | | | 6.9 (8.0) | | |     |
|      | Total trials (adjusted) | 8.0 (2.4) | | | 7.8 (2.8) | | |     |
| PRM  | Percent correct | 90.3 (13.3) | | | 91.07 (11.9) | | |     |
|      | Mean correct latency | 1942.4 (514.8) | | | 1730.4 (359.8) | | | 0.48 |
| IED  | Stages completed | 8.1 (1.9) | | | 8.7 (0.6) | | |     |
|      | Pre-ED errors | 9.6 (9.2) | | | 7.5 (3.1) | | |     |
|      | EDS errors | 6.4 (8.5) | | | 7.3 (8.5) | | |     |
| SWM  | Strategy | 34.8 (5.3) | -0.76 | 0.93 | 33.4 (5.5) | -0.52 | 0.95 |     |
|      | Between errors 4 boxes | 1.3 (2.4) | -0.43 | 1.45 | 0.8 (1.2) | -0.42 | 1.49 |     |
|      | Between errors 6 boxes | 6.9 (7.9) | -0.46 | 1.17 | 4.9 (5.2) | -0.09 | 0.82 |     |
|      | Between errors 8 boxes | 21.6 (13.5) | -0.48 | 1.04 | 17.2 (11.8) | -0.48 | 1.04 |     |
| SOC  | Problems solved in minimum moves | 8.5 (2.1) | | | 9.2 (2.0) | | |     |
|      | Mean initial thinking time 2 moves | 2445.6 (1732.3) | -0.28 | 1.46 | 2979.0 (2981.9) | -0.33 | 1.88 |     |
|      | Mean initial thinking time 3 moves | 6241.2 (4245.1) | -0.03 | 1.14 | 5181.1 (2600.0) | 0.28 | 0.56 |     |
|      | Mean initial thinking time 4 moves | 6906.5 (3849.4) | 0.46 | 0.75 | 8513.3 (6505.3) | 0.26 | 1.17 |     |
|      | Mean initial thinking time 5 moves | 9283.5 (6218.4) | 0.45 | 0.75 | 9072.6 (5555.2) | 0.48 | 0.65 |     |
|      | Mean subsequent thinking time 2 moves | 444.1 (314.2) | -0.24 | 0.34 | 370.7 (225.2) | -0.01 | 0.51 |     |
|      | Mean subsequent thinking time 3 moves | 4826.6 (6091.8) | -6.99 | 7.02 | 716.4 (817.0) | -0.06 | 0.75 |     |
|      | Mean subsequent thinking time 4 moves | 3185.8 (3656.9) | -0.74 | 1.63 | 1001.8 (866.8) | 0.38 | 0.41 |     |
|      | Mean subsequent thinking time 5 moves | 2932.8 (3270.5) | -0.82 | 1.53 | 1209.4 (1668.0) | -0.17 | 1.6 |     |
| AGN  | Mean correct latency | 557.3 (65.6) | | | 543.0 (51.8) | | |     |
|      | Total omissions | 22.0 (14.0) | | | 14.5 (9.1) | | | 0.65 |
|      | Total commissions | 24.3 (15.4) | | | 19.5 (9.1) | | |     |
Table 3: Continued.

| Task                                      | Outcome measure                          | Pretreatment | Posttreatment | ES |
|-------------------------------------------|------------------------------------------|--------------|---------------|----|
|                                           |                                          | Mean (SD)    | z-score mean  | z-score (SD) | z-score (SD) |    |
| Immediate free recall total correct      |                                          | 6.2 (1.7)    | 0.54          | 7.2 (2.0)    | -0.54        |    |
| Immediate free recall total novel words  |                                          | 0.3 (0.6)    | 0.0 (0.0)     | 0.0 (0.0)    | 0.0          |    |
| VRM \textsuperscript{a}                  | Immediate free recall total perseverations| 0.2 (0.9)    | 0.1 (0.4)     | 0.1 (0.2)    | 0.0          |    |
| Immediate recognition total correct \textsuperscript{b} |                                  | 22.7 (2.3)   | 2.3 (0.5)     | 2.7 (0.5)    | -0.06        |    |
| Immediate recognition total false positives \textsuperscript{a,c} |                              | 0.4 (1.1)    | 0.1 (0.2)     | 0.1 (0.2)    | 0.0          |    |
| Delayed recognition total correct        |                                          | 22.3 (2.6)   | 2.0 (1.5)     | 2.3 (1.5)    | 0.0          |    |
| Delayed recognition total false positives \textsuperscript{a,c} |                             | 0.7 (1.0)    | 0.7 (1.1)     | 0.7 (1.1)    | 0.0          |    |
|                                           |                                          |              |               |               |              |    |

Measures of time and latency are reported in milliseconds. Note that parallel forms were used when available. Normed scores (z-scores) are calculated for clinical mode tests (BLC, SOC, and SWM) and are presented when available.

%: percent change from pretreatment to posttreatment (note: percent differences that were significant at \( P < .05 \) are bolded; \( t \) values and significance values reported within the text); SD: standard deviation; EDS: extradimensional shift; ES: effect size (Cohen’s \( d \)); BLC: big circle/little circle; RTI: reaction time; DMS: delayed matching to sample; PAL: paired associates learning; PRM: pattern recognition memory; IED: intradimensional/extradimensional shift; SWM: spatial working memory; SOC: stockings of cambridge; AGN: affective go/no-go; VRM: verbal recognition memory.

\textsuperscript{a} Not included in MANOVAs for their respective domains due to lack of variation in measures (BLC, DMS, IED, and VRM measures) or inability to obtain a measure for the item in the majority of cases (SOC mean subsequent thinking time measures). Note these SOC measures showed changes in the expected direction, indicating at least numerical improvement for those who had a nonzero value for the measure (i.e., their movement time was less than their thinking time).

\textsuperscript{b} Approached significance (\( P = .06 \)).

\textsuperscript{c} Note that percent change was not calculated for the verbal recognition memory tasks of immediate free recall total novel words, immediate free recall total perseverations, immediate recognition total false positives, and delayed recognition total false positives due to the limited number of values other than 0.

Figure 2: Group percent change from baseline on tasks that significantly improved with duloxetine treatment is presented to give an indication of the magnitude of changes observed. RTI: reaction time; DMS: delayed matching to sample; PRM: pattern recognition memory; AGN: affective go/no-go; VRM: verbal recognition memory.
of visits included restlessness (29.7%), constipation (21.4%), increased perspiration (20.7%), and trouble achieving orgasm (20.0), and those occurring between 10.0–19.9% included frequent urination (19.3%), general malaise (18.6%), ringing in ears (17.2%), dizziness (17.2%), blurred vision (16.6%), dizziness on standing (15.1%), itching (15.1%), sleeping too much (14.5%), nausea/vomiting (13.8%), dry skin (11.7%), and diarrhea (11.7%). Side effects occurring less than 10% included tremors (9.7%), menstrual irregularity (7.6%), heart palpitation (6.2%), rash (6.2%), poor coordination (5.5%), chest pain (4.8%), painful urination (2.1%), and difficulty urinating (1.4%). It should be noted that some effects listed on the PRISE overlap with depressive symptomatology. On the FIBSER, the mean score for frequency of side effects attributed to duloxetine in Week 1 was 2.5 ± 2.0, which corresponds to a rate of 37% of the time. Mean score for severity was 2.7 ± 1.7, which is less than moderate, and interference with function was 2.0 ± 1.6, corresponding to “mild.” At Week 12, side effects were less frequent (mean score = 1.5 ± 2.0, corresponding to 17.5% of the time), less severe (mean score = 1.1 ± 1.7, corresponding to slightly over “trivial”) and interfered less with function (mean score = 0.5 ± 1.0, corresponding to less than “minimal”).

4. Conclusions

In this study, young-to middle-aged adults with MDD endorsing problems with concentration and/or decision making at presentation showed significant improvements in cognitive function after 12 weeks of treatment with duloxetine. The aspects of cognitive function that improved predominately involved psychomotor speed (both movement and thinking). Specific improvements were also noted on tasks assessing visual memory, decision making/response control for emotionally laden information, and verbal recognition memory. As expected, there was also a significant reduction in depressive symptoms with treatment. With the exception of the verbal immediate free recall task, cognitive improvements were independent of improvements in depressive symptom severity. These data suggest that persons who subjectively report cognitive impairment as a part of their depressive syndrome may realize cognitive improvements during duloxetine treatment. Specifically, psychomotor and mental processing speed may be improved with duloxetine treatment, spanning across several types of cognitive domains, and these improvements are not solely related to depressive symptom reduction.

Tasks in this study that significantly improved following duloxetine treatment yielded percent improvements ranging from 10% to 34%. It should be noted that while percent improvement is presented to help provide some equivalence of performance changes across tasks, a small percent improvement may be more important for one type of task than a larger improvement in another task. For example, small decreases in performance time that may be realized with treatment can be clinically meaningful, as cumulative decreases in the time needed to perform tasks can result in improved efficiency for depressed persons. Improved efficiency among depressed persons is important given the decreased productivity that is associated with MDD. The decreases in performance time that were observed following duloxetine treatment are important given their potential contribution to efficiency.

Interestingly, overall effects were significant for the two executive functioning domains, but post hoc analyses did not yield significant differences on specific outcome measures. Examination of the individual difference scores suggests that for the set-shifting and working memory domain, changes were occurring in the expected direction, but there may have been insufficient power to detect differences at the level of individual outcomes. For the spatial planning domain, examination of the difference scores suggests a more complicated picture in that changes in planning time were inconsistent among problems with varying numbers of moves. This may be explained in part by the fact that measures of mean subsequent thinking time cannot be evaluated for persons who are slower in the yoked control portion of the task.

The results of this study are similar to those observed by Herrera-Guzmán et al. [35, 36] following duloxetine treatment in several ways but differ in some important ways as well. First, both studies noted improvements in psychomotor speed and mental processing that spanned several cognitive domains, with two of the individual tasks (RTI five-choice movement time and PRM mean correct latency) significantly improving in both studies and one (DMS mean correct latency) significantly improving in the current study and approaching significance ($P=.051$) in the Herrera-Guzmán study [35]. Herrera-Guzmán [35] found several significant improvements in visual memory, which were observed in a more limited manner in the current study (i.e., on the percent correct measure of one of the visual memory tasks). Both studies noted significant improvements in verbal learning as well, a finding that was also obtained by Raskin et al. [16] in their examination of duloxetine on cognitive function in elderly patients with MDD. The current study failed to see the expected improvements on individual tests of executive function that were observed in the Herrera-Guzmán et al. [36] study. However, we believe this is likely due to insufficient power in our sample given the fact that we found significant overall effects in the executive function domains as described above. Both studies also observed cognitive improvements that were independent of symptom severity. The similarities between these studies are noteworthy given the significant overlap in the design of the two studies including a similar age range and the use of the CANTAB, and they are also important in that the current study did not solely evaluate cognition in individuals who showed a clinical response to treatment.

Limitations of this study include the small sample size and open-label treatment. In addition, a nondepressed control group was not assessed for comparison of baseline performance. While participants were required to endorse cognitive difficulties for study eligibility, it is not necessarily true that this endorsement would reflect objectively measurable pretreatment difficulties in all of the cognitive domains assessed. Thus, absence of improvement in some domains may be the result of normal baseline performance to begin with, which cannot be addressed without a control group.
was a first step in understanding how duloxetine may affect cognitive performance in individuals subjectively reporting cognitive difficulties, future studies are needed to examine the effects of duloxetine in patients with established objective cognitive impairment associated with their depression. However, in the current study, participants served as their own control and one could argue that it may be more important, or at least equally important, to determine improvements at the individual level rather than by comparison to healthy controls. There is a great deal of individual variation on task performance, and improvement is relative to how participants perform when they are not depressed. Thus, we believe that the meaningfulness of the results of this study lies in the fact that participants who before treatment endorsed impairment that was causing them difficulty in their daily lives showed improvement on cognitive tasks following duloxetine treatment, as well as subjective report that their cognition had improved. Defining improvement solely based on norms or comparisons to nondepressed controls may very well miss clinically meaningful improvements in cognitive function for depressed individuals. Another potential limitation of this study is the possibility that observed improvements were due to practice effects and/or the development of an efficient problem-solving strategy for the task (i.e., some tasks may have limited utility to detect changes once an effective problem-solving strategy is adopted and the task is no longer novel). Parallel forms were used for available tests in an attempt to avoid practice effects, but the possibility of practice effects cannot be completely eliminated, particularly for those tests for which only the clinical version was available.

As mentioned previously, an important aspect of this study is the use of a subjective (self-report) assessment to screen for cognitive impairment prior to treatment. Currently no gold standard screening approach exists for cognitive dysfunction that is representative of impairment on all domains thought to be associated with MDD. The approach used in this study follows what is most likely to be effectively implemented in clinical practice. This study evaluated both baseline subjective evaluation and clinician-rated evaluation of cognitive function, in addition to objective assessment of cognitive performance. Improvements were observed in all of these areas following treatment, suggesting that assessment of subjective functioning may be a useful proxy for assessing cognitive impairment. This is important given the practical implausibility of utilizing objective testing in a busy clinical practice. However, the results of this study are preliminary, and further work is needed to determine the best approach to measuring cognitive changes in response to treatment and the potential relationship between subjective and objective cognitive impairment in depression.

The results of this study support the use of duloxetine for individuals whose presentation of depression includes cognitive impairments. The lack of relationship between symptom severity and cognitive performance suggests that duloxetine may exert a positive effect on cognitive function independently of depressive symptoms, consistent with previous reports suggesting the same [36]. Therefore, it is conceivable that duloxetine may also be a potential augmenting agent for depressed individuals with residual cognitive symptoms following initial antidepressant treatment. Further examination of the potential benefit of duloxetine as a targeted treatment strategy for cognitive function in depression is recommended.

Conflict of Interests

Eli Lilly and Company provided funding and duloxetine for this investigator-initiated trial (Prabha Sunderajan, PI). Dr. Parbha Sunderajan has also received funding from Takeda Pharmaceuticals North America, Inc. and Bristol-Myers Squibb. Dr. Tracy L. Greer has received research funding from NARSAD and is a paid consultant for H. Lundbeck A/S and Takeda Pharmaceuticals International, Inc. Mr. Bruce D. Grannemann has no disclosures to report. Dr. Kurian has received research grant support from Targacept, Inc; Pfizer, Inc., Johnson & Johnson, Evotec, Inc., Rexam Pharmaceuticals, Naurex, Inc., Forest Pharmaceuticals, and the National Institute of Mental Health (NIMH). Dr. Madhukar H. Trivedi is or has been an advisor/consultant to, or on the Speakers' Bureaus for, Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly and Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexam Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received research support from Agency for Healthcare Research and Quality (AHRQ), Concept Therapeutics, Inc., Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), and Solvay Pharmaceuticals, Inc.

References

[1] H. O. F. Veiel, “A preliminary profile of neuropsychological deficits associated with major depression,” Journal of Clinical and Experimental Neuropsychology, vol. 19, no. 4, pp. 587–603, 1997.
[2] R. Elliot, “Executive functions and their disorders,” British Medical Bulletin, vol. 65, no. 1, pp. 49–59, 2003.
[3] N. I. Landro, T. C. Stiles, and H. Sletvold, “Neuropsychological function in nonpsychotic unipolar major depression,” Neuropsychiatry, Neuropsychology and Behavioral Neurology, vol. 14, no. 4, pp. 233–240, 2001.
[4] C. Sobin and H. A. Sackei, “Psychomotor symptoms of depression,” American Journal of Psychiatry, vol. 154, no. 1, pp. 4–17, 1997.
[5] M. A. Butters, E. M. Whyte, R. D. Nebes et al., “The nature and determinants of neuropsychological functioning in late-life depression,” Archives of General Psychiatry, vol. 61, no. 6, pp. 587–595, 2004.

[6] L. L. Judd, H. S. Akiskal, P. J. Zeller et al., “Psychosocial disability during the long-term course of unipolar major depressive disorder,” Archives of General Psychiatry, vol. 57, no. 4, pp. 375–380, 2000.

[7] L. L. Judd, P. J. Schettler, D. A. Solomon et al., “Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders,” Journal of Affective Disorders, vol. 108, no. 1-2, pp. 49–58, 2008.

[8] E. Bromet, L. H. Andrade, I. Hwang et al., “Cross-national epidemiology of DSM-IV major depressive episode,” BMC Medicine, vol. 9, article 90, 2011.

[9] R. C. Kessler, H. S. Akiskal, M. Ames et al., “Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers,” American Journal of Psychiatry, vol. 163, no. 9, pp. 1561–1568, 2006.

[10] K. R. Merikangas, M. Ames, L. Cui et al., “The impact of comorbidity of mental and physical conditions on role disability in the US adult household population,” Archives of General Psychiatry, vol. 64, no. 10, pp. 1180–1188, 2007.

[11] J. Jaeger, S. Berns, S. Uzelac, and S. Davis-Conway, “Neurocognitive deficits and disability in major depressive disorder,” Psychiatry Research, vol. 145, no. 1, pp. 39–48, 2006.

[12] M. H. Trivedi, D. W. Morris, S. R. Wisniewski et al., “Increase in work productivity of depressed individuals with improvement in depressive symptom severity,” American Journal of Psychiatry, vol. 170, no. 6, pp. 633–641, 2013.

[13] B. J. McIntosh, X. Y. Zhang, T. Kosten et al., “Performance-based assessment of functional skills in severe mental illness: results of a large-scale study in China,” Journal of Psychiatric Research, vol. 45, no. 8, pp. 1089–1094, 2011.

[14] G. B. Cassano, F. Puca, P. L. Scapicchio et al., “Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nonremitted elderly patients,” Journal of Clinical Psychiatry, vol. 63, no. 5, pp. 396–402, 2002.

[15] R. Gallassi, R. Di Sarro, A. Morreale, and M. Amore, “Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy,” Journal of Affective Disorders, vol. 91, no. 2-3, pp. 243–250, 2006.

[16] J. Raskin, C. G. Wiltsie, A. Siegal et al., “Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial,” American Journal of Psychiatry, vol. 164, no. 6, pp. 900–909, 2007.

[17] Y. Levkovitz, R. Caftori, A. Avital, and G. Richter-Levin, “The SSRIss drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression,” Brain Research Bulletin, vol. 58, no. 4, pp. 345–350, 2002.

[18] J. S. Richardson, D. L. Keegan, R. C. Bowen et al., “Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline,” International Clinical Psychopharmacology, vol. 9, no. 1, pp. 35–40, 1994.

[19] M. Fava, L. M. Graves, F. Benazzi et al., “A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment,” Journal of Clinical Psychiatry, vol. 67, no. 11, pp. 1754–1759, 2006.

[20] C. T. Gualtieri, L. G. Johnson, and K. B. Benedict, “Neurocognition in depression: patients on and off medication versus healthy comparison subjects,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 18, no. 2, pp. 217–225, 2006.

[21] Á. Hammar, A. Lund, and K. Hugdahl, “Long-lasting cognitive impairment in unipolar major depression: a 6-month follow-up study,” Psychiatry Research, vol. 118, no. 2, pp. 189–196, 2003.

[22] P. Weiland-Fiedler, K. Erickson, T. Waldeck et al., “Evidence for continuing neuropsychological impairments in depression,” Journal of Affective Disorders, vol. 82, no. 2, pp. 253–258, 2004.

[23] D. J. Smith, W. J. Muir, and D. H. R. Blackwood, “Neurocognitive impairment in euthymic young adults with bipolar spectrum disorder and recurrent major depressive disorder,” Bipolar Disorders, vol. 8, no. 1, pp. 40–46, 2006.

[24] Y. Paelecke-Habermann, J. Pohl, and B. Leplow, “Attention and executive functions in remitted major depression patients,” Journal of Affective Disorders, vol. 89, no. 1-3, pp. 125–135, 2005.

[25] B. T. Kurian, T. L. Greer, and M. H. Trivedi, “Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms,” Expert Review of Neurotherapeutics, vol. 9, no. 7, pp. 975–984, 2009.

[26] L. L. Judd, M. J. Paulus, P. J. Schettler et al., “Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?” American Journal of Psychiatry, vol. 157, no. 9, pp. 1501–1504, 2000.

[27] T. L. Greer, B. T. Kurian, and M. H. Trivedi, “Defining and measuring functional recovery from depression,” CNS Drugs, vol. 24, no. 4, pp. 267–284, 2010.

[28] M. J. Detke, Y. Lu, D. J. Goldstein, J. R. Hayes, and M. A. Demitrack, “Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 63, no. 4, pp. 308–315, 2002.

[29] D. J. Goldstein, C. Mallinckrodt, Y. Lu, and M. A. Demitrack, “Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial,” Journal of Clinical Psychiatry, vol. 63, no. 3, pp. 225–231, 2002.

[30] A. F. Schatzberg, “Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder,” Journal of Clinical Psychiatry, vol. 64, no. 13, pp. 30–37, 2003.

[31] T. Kihara and M. Ikeda, “Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex,” Journal of Pharmacology and Experimental Therapeutics, vol. 272, no. 1, pp. 177–183, 1995.

[32] M. H. Trivedi, D. Desai, M. J. Ossanna, Y. L. Pritchett, S. K. Brannan, and M. J. Detke, “Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine,” International Clinical Psychopharmacology, vol. 23, no. 3, pp. 161–169, 2008.

[33] A. F. T. Arnsten, “Catecholamine influences on dorsolateral prefrontal cortical networks,” Biological Psychiatry, vol. 69, no. 12, pp. e89–e99, 2011.

[34] S. M. Stahl, “Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex,” Journal of Clinical Psychiatry, vol. 70, no. 5, pp. 617–618, 2009.

[35] I. Herrera-Guzmán, E. Gudayol-Ferré, D. Herrera-Guzmán, J. Guárdia-Olmos, E. Hinojosa-Calvo, and J. E. Herrera-Abarca, “Effects of selective serotonin reuptake and dual serotonin-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder,” Journal of Psychiatric Research, vol. 43, no. 9, pp. 855–863, 2009.
[36] I. Herrera-Guzmán, J. E. Herrera-Abarca, E. Gudayol-Ferré et al., “Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder,” *Psychiatry Research*, vol. 177, no. 3, pp. 323–329, 2010.

[37] S. M. McClintock, M. M. Husain, T. L. Greer, and C. M. Cullum, “Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis,” *Neuropsychology*, vol. 24, no. 1, pp. 9–34, 2010.

[38] T. Beblo, B. Baumann, B. Bogerts, C. W. Wallesch, and M. Hermann, “Neuropsychological correlates of major depression: a short-term follow-up,” *Cognitive Neuropsychiatry*, vol. 4, no. 4, pp. 333–341, 1999.

[39] E. Biringer, A. Lundervold, K. Stordal et al., “Executive function improvement upon remission of recurrent unipolar depression,” *European Archives of Psychiatry and Clinical Neuroscience*, vol. 255, no. 6, pp. 373–380, 2005.

[40] CANTAB Eclipse Test Administration Guide, Cambridge Cognition Limited, 2004.

[41] A. J. Rush, D. E. Giles, and M. A. S. Schlesser, “The inventory for depressive symptomatology (IDS): preliminary findings,” *Psychiatry Research*, vol. 18, no. 1, pp. 65–87, 1986.

[42] M. Hamilton, “A rating scale for depression,” *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 23, pp. 56–62, 1960.

[43] W. Guy, *ECDEU Assessment Manual for Psychopharmacology*, revised (DHEW publication no. ADM 76-338), U.S. Government Printing Office, Washington, DC, USA, 1976.

[44] H. A. Sackeim, “The definition and meaning of treatment-resistant depression,” *Journal of Clinical Psychiatry*, vol. 62, no. 16, pp. 10–17, 2001.

[45] M. B. First, R. L. Spitzer, M. Gibbon, and J. B. W. Williams, *Structured Clinical Interview for DSM-IV Axis I Disorders Clinician Version (SCID-I-CV)*, Biometrics Research Department, New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York, NY, USA, 1995.

[46] J. R. Blair and O. Spreen, “Predicting premorbid IQ: a revision of the National Adult Reading Test,” *Clinical Neuropsychologist*, vol. 3, no. 2, pp. 129–136, 1989.

[47] C. A. Sanislow, D. S. Pine, K. J. Quinn et al., “Developing constructs for psychopathology research: research domain criteria,” *Journal of Abnormal Psychology*, vol. 119, no. 4, pp. 631–639, 2010.

[48] T. Insel, B. Cuthbert, M. Garvey et al., “Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders,” *American Journal of Psychiatry*, vol. 167, no. 7, pp. 748–751, 2010.

[49] M. H. Trivedi, A. J. Rush, S. R. Wisniewski et al., “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice,” *American Journal of Psychiatry*, vol. 163, no. 1, pp. 28–40, 2006.

[50] A. J. Rush, M. Fava, S. R. Wisniewski et al., “Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design,” *Controlled Clinical Trials*, vol. 25, no. 1, pp. 119–142, 2004.

[51] S. R. Wisniewski, A. J. Rush, G. K. Balasubramani, M. H. Trivedi, and A. A. Nierenberg, “Self-rated global measure of the frequency, intensity, and burden of side effects,” *Journal of Psychiatric Practice*, vol. 12, no. 2, pp. 71–79, 2006.

[52] J. Cohen and P. Cohen, *Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences*, Lawrence Erlbaum Associates, Hillsdale, NJ, USA, 2nd edition, 1983.